Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease (SEST-MOYA)

Capital Medical University

Status: Enrolling

Conditions: Moyamoya Disease

Treatments: Drug: Revascularization/Conservative management

Study type: Observational

Funder types: Other

Identifiers

NCT06817434

KY2023-297-02

Details and patient eligibility

About

The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.

Enrollment: 330 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The imaging examination meets the diagnostic criteria for moyamoya disease;
2. Sign the informed consent form;
3. Age ≥18 years old;
4. Baseline mRS score ≤2 points;
5. The patient receives revascularization/conservative treatment;
6. There is at least 1 imaging follow-up result.

Exclusion criteria

1. Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome;
2. Individuals under the age of 18;
3. Participants who refuse to take part in this study;
4. Pregnant patients;
5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus;
6. A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease;
7. Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation;
8. Allergies to contrast media;
9. Patients with missing imaging data or whose image quality cannot be analyzed;
10. Individuals who refuse or are unable to undergo imaging follow-up;
11. Patients receiving other types of lipid-lowering drug treatments.